Scalper1 News
Shares of development-stage pharmaceutical firm Esperion Therapeutics (ESPR) jumped 11% Wednesday after UBS initiated coverage of Esperion stock with a buy rating, praising its cholesterol drug candidate. Analyst Andrew Peters wrote that ETC-1002, a drug lowering LDL cholesterol that yielded positive phase 2b trial results last month, could present further upside even for a stock that’s already more than doubled this year. He says that the drug Scalper1 News
Scalper1 News